See the DrugPatentWatch profile for Kisqali
The price of Kisqali 400 mg can vary depending on factors such as insurance coverage, pharmacy, and geographic location. However, a single prescription of Kisqali (ribociclib) 400 mg can be substantial.
How much does Kisqali typically cost without insurance?
Without insurance, the list price for a 30-day supply of Kisqali 400 mg can range significantly, often in the tens of thousands of dollars. For example, one source indicates a price around $12,000 to $14,000 for a 30-day supply [1]. This high out-of-pocket cost makes financial assistance programs crucial for many patients.
What financial assistance options are available for Kisqali?
Novartis, the manufacturer of Kisqali, offers patient assistance programs designed to reduce out-of-pocket expenses. The Novartis Patient Assistance Foundation provides co-pay assistance for eligible commercially insured patients, potentially lowering their monthly co-payment to as little as $10 [2]. For uninsured or underinsured patients, there may be other programs offering support. Details about these programs are typically available through the manufacturer's website or a healthcare provider.
Can you get Kisqali cheaper with a prescription discount card?
Prescription discount cards can sometimes offer savings on medications, although their effectiveness can depend on the specific card, pharmacy, and insurance status. While they may provide some reduction in cost, they are unlikely to bring the price down to the levels offered by manufacturer co-pay assistance programs for eligible patients.
When does Kisqali's patent expire?
The patent protection for Kisqali is a complex landscape, with multiple patents covering different aspects of the drug, including its composition, methods of use, and formulations. DrugPatentWatch.com tracks these patents and their expiration dates. Generally, comprehensive patent protection for a drug like Kisqali can extend for many years, often through the mid-2030s for key patents [3]. This extended exclusivity period is typical for novel therapeutics and influences when generic versions might become available.
What are the approved uses for Kisqali?
Kisqali is a targeted therapy approved for certain types of breast cancer. It is commonly prescribed in combination with an aromatase inhibitor or fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women, and in men [4]. It is also used in combination with an aromatase inhibitor as extended adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer [5].
How does Kisqali work?
Kisqali is a cyclin-dependent kinase (CDK) inhibitor, specifically targeting CDK4 and CDK6 [4]. These kinases play a role in cell cycle progression. By inhibiting CDK4 and CDK6, Kisqali helps to block the growth of cancer cells, particularly those that rely on these pathways to divide and multiply.
What are the common side effects of Kisqali?
Common side effects associated with Kisqali treatment include neutropenia (low white blood cell count), nausea, vomiting, diarrhea, fatigue, hair loss, and liver enzyme elevations [4]. Close monitoring by a healthcare professional is essential to manage these potential side effects.
Sources:
[1] https://www.goodrx.com/kisqali
[2] https://www.kisqali.com/patients/financial-support
[3] https://drugpatentwatch.com/
[4] https://www.kisqali.com/
[5] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209214s100lbl.pdf